Navigation Links
Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
Date:10/28/2008

Company Also Announces Completion of Enrollment in U.S. Phase II Study of Nitazoxanide in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1

TAMPA, Fla., Oct. 28 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced the presentation of studies of nitazoxanide at the upcoming 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting(R), and the 50th Anniversary Meeting of the International Association for the Study of the Liver (IASL) in San Francisco, October 31 - November 4, 2008.

Nitazoxanide Abstracts

-- "Evaluation of a 4 Week Lead-In Phase with Nitazoxanide (NTZ) Prior

to Peginterferon (PEGIFN) Plus NTZ for Treatment of Chronic Hepatitis C:

Final Report," J. Rossignol et al., Sunday, November 2, 4:15 PM PST

(Oral Session IASL #87), and Tuesday, November 4, 8:00 AM - 12:30 PM

PST (AASLD Presidential Poster #1848)

-- "Potential Role for Nitazoxanide in Combination with STAT-C Agents

for the Inhibition of HCV Replication Without the Development of

Resistance," Korba, et al. Sunday Nov. 2, 5:30 PM PST (Oral Session

#115)

-- "Nitazoxanide (NTZ) is an Inducer of eIF2a and PKR

phosphorylation," Elazar et al., Tuesday, November 4, 8:00 AM -

12:30 PM PST (Poster #1881)

STEALTH C-3 Fully Enrolled

In addition, Romark announced it has completed enrollment of patients into its U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C genotype 1 (STEALTH C-3). The STEALTH C-3 (Studies to Evaluate Alinia for Treatment of Hepatitis C) study began enrollment in April 2008, and 112 patients were ultimately enrolled at 13 centers in the U.S. Data from a planned interim analysis is expected in early 2009.

A Phase II randomized, double-blind, placebo-controlled clinical trial, STEALTH C-3 is designed to evaluate the safety and efficacy of nitazoxanide in combination with peginterferon alfa-2a (Pegasys(R), Roche) and ribavirin (Copegus(R), Roche) in treatment naive patients with chronic hepatitis C infected with genotype 1. The primary objective of this trial is to evaluate sustained virologic response (SVR) with a treatment regimen of 4 weeks of nitazoxanide lead-in therapy followed by 48 weeks of standard of care plus nitazoxanide versus 4 weeks of placebo lead-in followed by 48 weeks of standard of care and placebo.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood. A large majority of those infected do not show symptoms, but fatigue, abdominal pain and nausea can be common. The current standard treatment of care, peginterferon and ribavirin, is effective in about half of all patients treated. According to the Centers for Disease Control, HCV affects an estimated 4.1 million Americans.

About Romark Laboratories

Romark Laboratories (http://www.romark.com), a privately held biopharmaceutical company, has discovered and developed a new class of small molecule antivirals known as thiazolides. The Company is developing nitazoxanide, the first of the thiazolide class, for the treatment of chronic hepatitis C, and is developing other new thiazolides for treating viral diseases including chronic hepatitis B. Alinia(R) (nitazoxanide) is approved by the U.S. Food and Drug Administration and marketed by Romark for the treatment of infections caused by Cryptosporidium or Giardia.


'/>"/>
SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
4. Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
5. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
6. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
7. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
8. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
9. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
10. AIT Laboratories Expands Pharma Services
11. TriMix Laboratories Announces New Partnership With American Pharmacy Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):